Neway Enters Strategic Lab Services Arrangement With Quest Diagnostics To Speed Quality End-Stage Renal Disease Testing
Portfolio Pulse from Benzinga Newsdesk
Neway has entered into a strategic lab services arrangement with Quest Diagnostics (DGX) to expedite quality end-stage renal disease testing. This partnership is expected to enhance the efficiency and accuracy of testing, benefiting patients with kidney diseases.
October 06, 2023 | 5:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics has entered into a strategic partnership with Neway to expedite end-stage renal disease testing. This could potentially increase the company's market share in the medical testing industry.
The partnership with Neway could potentially increase Quest Diagnostics' market share in the medical testing industry. This is because the partnership is aimed at enhancing the efficiency and accuracy of end-stage renal disease testing, which could attract more customers to the company. Therefore, this news is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100